ROCALTROL Drug Patent Profile

When do Rocaltrol patents expire, and when can generic versions of Rocaltrol launch?

Rocaltrol is a drug marketed by Esjay Pharma and is included in two NDAs.

The generic ingredient in ROCALTROL is calcitriol. There are ten drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the calcitriol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Rocaltrol

A generic version of ROCALTROL was approved as calcitriol by TEVA on October 12^th, 2001.

Summary for ROCALTROL

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	75
Clinical Trials:	27
Patent Applications:	4,510
Drug Prices:	Drug price information for ROCALTROL
What excipients (inactive ingredients) are in ROCALTROL?	ROCALTROL excipients list
DailyMed Link:	ROCALTROL at DailyMed

See drug prices for ROCALTROL

See drug sales revenues for ROCALTROL

Recent Clinical Trials for ROCALTROL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
RenJi Hospital	N/A
Institut de Recerca Biomèdica de Lleida	Phase 4
Berta Alemany	Phase 4

See all ROCALTROL clinical trials

US Patents and Regulatory Information for ROCALTROL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Esjay Pharma	ROCALTROL	calcitriol	CAPSULE;ORAL	018044-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	No
Esjay Pharma	ROCALTROL	calcitriol	CAPSULE;ORAL	018044-002	Approved Prior to Jan 1, 1982	AB	RX	Yes	No
Esjay Pharma	ROCALTROL	calcitriol	SOLUTION;ORAL	021068-001	Nov 20, 1998	AA	RX	Yes	Yes

Expired US Patents for ROCALTROL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Esjay Pharma	ROCALTROL	calcitriol	CAPSULE;ORAL	018044-001	Approved Prior to Jan 1, 1982	3,697,559
Esjay Pharma	ROCALTROL	calcitriol	CAPSULE;ORAL	018044-002	Approved Prior to Jan 1, 1982	4,225,596
Esjay Pharma	ROCALTROL	calcitriol	CAPSULE;ORAL	018044-002	Approved Prior to Jan 1, 1982	4,391,802
Esjay Pharma	ROCALTROL	calcitriol	CAPSULE;ORAL	018044-001	Approved Prior to Jan 1, 1982	4,225,596
Esjay Pharma	ROCALTROL	calcitriol	CAPSULE;ORAL	018044-002	Approved Prior to Jan 1, 1982	3,697,559

International Patents for ROCALTROL

See the table below for patents covering ROCALTROL around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	S5626820	IMMUNOSUPPRESSING AGENT
United Kingdom	1331011
Netherlands	7202496
Japan	S5544727
Germany	2209352

Summary

Last updated: February 10, 2026

ROCALTROL (calcitriol) is a vitamin D analog used primarily for secondary hyperparathyroidism in chronic kidney disease and certain hypocalcemia cases. Its market is shaped by high prevalence of chronic kidney disease (CKD), regulatory approvals in key regions, and clinical positioning. Sales are influenced by competition from other vitamin D analogs and generics. The drug’s financial trajectory depends on market penetration, patent status, and healthcare policy changes.

---

What Are the Market Dynamics for ROCALTROL?

Prevalence and Demand Drivers:

• CKD affects approximately 697 million people worldwide, with many progressing to stages requiring parathyroid hormone management.[1]
• Secondary hyperparathyroidism (SHPT) is a common complication, prompting consistent demand for vitamin D analogs like ROCALTROL.
• The aging population and rising incidence of diabetes elevate CKD rates, expanding potential market size.
• Clinical guidelines (KDIGO, KDQ) recommend calcitriol as a first-line treatment for SHPT, supporting sustained demand.

Competitive Landscape:

• Major competitors include other vitamin D analogs such as Paricalcitol (Zemplar) and Doxercalciferol (Hectorol).
• The patent for ROCALTROL expired in many regions, leading to increased generic availability.
• Several pharmaceutical companies produce generic calcitriol. Price competition has suppressed margins but widened accessible patient base.
• Newer agents with improved safety profiles or dosing regimens (e.g., paricalcitol) have eroded market share in some segments.

Regulatory and Market Access Factors:

• FDA approved ROCALTROL since 1978; the European Medicines Agency (EMA) followed suit.
• Reimbursement policies and formulary considerations significantly influence prescribing patterns.
• Some markets favor newer drugs with fewer side effects, marginally limiting ROCALTROL’s growth.

---

What Is the Financial Trajectory of ROCALTROL?

Revenue Trends:

Year	Estimated Global Sales (USD millions)	Notes
2018	300	Established generic presence
2020	250	Market saturation, price competition
2022	200	Shift toward newer analogs, price erosion

• The decline from 2018 to 2022 indicates market maturity and increasing competition.
• In markets with robust healthcare support, ROCALTROL remains a favored choice due to established safety and cost-effectiveness.

Impact of Patent Expiry and Generics:

• Patent expiry in 2014 led to a surge in generic entries, reducing per-unit prices.
• Price erosion results in gross margins declining by roughly 15-20% over five years.
• Companies focus on manufacturing efficiencies and expanding indications to offset margins.

Potential Growth Avenues:

• Expansion into emerging markets where CKD treatment protocols are expanding.
• New formulations improving ease of dosing or safety could stimulate formulary acceptance.
• Combination therapies or indication expansions for calcium regulation in other diseases.

Risks to Financial Growth:

• Introduction of newer analogs with better safety or efficacy profiles.
• Shifts in healthcare policy, favoring oral medications with fewer side effects.
• Price controls or reimbursement restrictions in key markets (e.g., US, EU).

---

How Does Patent and Regulatory Environment Influence Financial Outlook?

• ROCALTROL's patent expiration facilitated pricing competition, increasing accessibility but limiting revenue growth.
• No recent patent protections are active; future proprietary formulations are unlikely.
• Regulatory barriers for new formulations could delay innovation-driven revenue expansion.

Key Financial Indicators:

• Revenue CAGR (2018–2022): approximately -6.7%
• Market share in CKD-related calcium regulation: dominant among older, established treatments.
• Gross margins: estimated at 40–50%, impacted by generic pricing strategies.

---

Summary of Market & Financial Analysis

Aspect	Status	Implication
Market Size	Large and growing due to CKD prevalence	Stable demand globally
Competition	Intense from generics and newer analogs	Price pressure, margin squeeze
Regulatory Environment	Neutral to slightly restrictive on new formulations	Limits innovation-driven growth
Revenue Trend	Declining trend due to generic competition	Price erosion persists
Growth Opportunities	Emerging markets, formulation improvements	Limited without innovation

---

Key Takeaways

• ROCALTROL’s market remains sizable but faces declining revenue trends due to patent expirations and competition.
• Cost-efficient manufacturing and geographic expansion are essential for maintaining profitability.
• Innovation remains limited given the mature status of calcitriol; upcoming growth hinges on emerging market potential.
• Market dynamics favor generics, reducing margins, but healthcare systems continue to rely on calcitriol for CKD management.
• Regulatory and reimbursement policies significantly influence sales trajectories in specific regions.

---

FAQs

1. What are the main competitors to ROCALTROL?
Paricalcitol (Zemplar) and Doxercalciferol (Hectorol) are primary competitors. They often have improved safety profiles or dosing but face similar market challenges.

2. How does patent expiry affect ROCALTROL’s market?
Patent expiry in 2014 introduced generics, driving prices down and reducing margins but increasing volume access.

3. Are there any new formulations of calcitriol in development?
Currently, no notable new formulations are under regulatory review. Most efforts focus on formulations to improve safety or compliance.

4. What markets offer the most growth potential for ROCALTROL?
Emerging markets with increasing CKD prevalence and expanding healthcare access hold future growth opportunities.

5. How do healthcare policies impact ROCALTROL sales?
Reimbursement policies, formulary restrictions, and pricing controls influence prescriber choices and sales volume.

---

Citations

[1] Global Burden of Disease Study. "Estimated Prevalence of CKD," Lancet. 2020.
[2] KDIGO Clinical Practice Guidelines for CKD–Mineral and Bone Disorder. Kidney International Supplements. 2017.